Metástasis

Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET

Monday, June 7, 2021 - 9:05pm

The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.

Key Points: 
  • The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis).
  • The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties.
  • Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements.

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Tuesday, June 1, 2021 - 12:05pm

This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer.

Key Points: 
  • This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer.
  • TGF plays a key role in fibrosis and also promotes cancer growth and metastasis via its effects in the tumor microenvironment (TME).
  • The integrins v6 and v8 are expressed by cancer cells, and v6 is also expressed on epithelial cells in fibrotic diseases.
  • Corbus believes targeting both integrins at once is a rational approach to treating fibrotic diseases and carcinomas.

Golf Tournament for Young Woman Lost to Metastatic Breast Cancer

Friday, May 28, 2021 - 12:36am

ASSONET, Mass., May 27, 2021 /PRNewswire/ -- Play golf, fight cancer.

Key Points: 
  • ASSONET, Mass., May 27, 2021 /PRNewswire/ -- Play golf, fight cancer.
  • On Friday, September 10, 2021, Piping Systems Inc. hosts its 4th Annual Tee for Cancer Free Golf Tournament atThe Fall River Country Club to honor Megan Lally, who sadly lost her battle to metastatic breast cancer on September 1, 2011.
  • The event is organized by Piping Systems, Inc., a well known piping contractor in Massachusetts, to benefit The Megan Lally Memorial Fund.
  • Pauline Lally, President of Piping Systems Inc., and Megan's mom helped form The Megan Lally Memorial Fund with Megan's friends and loved ones.Proceeds from the golf sponsorships fund the research for Metastatic Breast Cancer.

AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells

Wednesday, May 26, 2021 - 2:00pm

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (AXIM Biotech, AXIM or the Company), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has completed pre-clinical drug studies on its patent pending compound SPX-1009, demonstrating the suppression of malignant metastatic melanoma cells.

Key Points: 
  • SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (AXIM Biotech, AXIM or the Company), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has completed pre-clinical drug studies on its patent pending compound SPX-1009, demonstrating the suppression of malignant metastatic melanoma cells.
  • We are extremely excited with the results of the in vitro testing, said John W. Huemoeller II, Chief Executive Officer of AXIM Biotechnologies, Inc.
  • This potential therapeutic treatment could someday help control melanoma growth and metastasis with our compound SPX-1009 in a topical treatment.
  • Founded in 2014, AXIM Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19).

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Wednesday, May 26, 2021 - 2:15pm

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life.

Key Points: 
  • The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life.
  • The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis).
  • The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties.

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting

Wednesday, May 19, 2021 - 10:04pm

b'Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.

Key Points: 
  • b'Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.
  • Tumor infiltrating lymphocyte (TIL) therapy uses a patient\xe2\x80\x99s own immune cells to attack cancer.
  • TIL cells are extracted from a patient\xe2\x80\x99s own tumor tissue, expanded through a proprietary process, and infused back into the patient.
  • The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer.

Susan G. Komen and Amgen to Help People Understand and Monitor Breast and Bone Health

Wednesday, May 19, 2021 - 7:45pm

b'Susan G. Komen \xc2\xae, the world\xe2\x80\x99s leading breast cancer organization, today unveiled a new integrated campaign, in partnership with Amgen, to educate the breast cancer community about the link between breast and bone health, providing useful information for women of all ages and stages of breast cancer.\n\xe2\x80\x9cBreast cancer treatment can affect bone health, and it is one of main areas where breast cancers spread when they metastasize.

Key Points: 
  • b'Susan G. Komen \xc2\xae, the world\xe2\x80\x99s leading breast cancer organization, today unveiled a new integrated campaign, in partnership with Amgen, to educate the breast cancer community about the link between breast and bone health, providing useful information for women of all ages and stages of breast cancer.\n\xe2\x80\x9cBreast cancer treatment can affect bone health, and it is one of main areas where breast cancers spread when they metastasize.
  • Yet no matter your age, health or breast cancer diagnosis, your bone health may also be at risk,\xe2\x80\x9d said Paula Schneider, president and CEO of Susan G. Komen and a breast cancer survivor.
  • \xe2\x80\x9cWomen have long known that it is important to understand what is normal for their breast health and to talk to their doctor if they notice any changes.
  • Women need to include their bones in this moment of vigilance.\xe2\x80\x9d\nMetastatic breast cancer, also known as stage IV breast cancer, is when the breast cancer spreads beyond the breast and nearby lymph nodes to other parts of the body, often the bones.

Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST

Friday, May 7, 2021 - 1:30pm

The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.

Key Points: 
  • The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently.
  • Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis).
  • The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties.
  • Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements.

Iovance Biotherapeutics to Present at Upcoming Conferences

Tuesday, May 4, 2021 - 9:30pm

Tumor infiltrating lymphocyte (TIL) therapy uses a patient\xe2\x80\x99s own immune cells to attack cancer.

Key Points: 
  • Tumor infiltrating lymphocyte (TIL) therapy uses a patient\xe2\x80\x99s own immune cells to attack cancer.
  • TIL cells are extracted from a patient\xe2\x80\x99s own tumor tissue, expanded through a proprietary process, and infused back into the patient.
  • The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer.
  • Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.

$26.45 Billion Circulating Tumor Cells Market by Technology; Application; Product; Specimen - Global Forecast to 2028 - ResearchAndMarkets.com

Tuesday, May 4, 2021 - 11:42am

Though circulating tumor cells technology is still under research phase but used for the prognosis of several cancer forms including, breast, melanoma, lung, colon, pancreas, and glioblastoma.\nIn the future, doctors would have a better chance of fighting cancer via liquid biopsies, and researchers would detect circulating tumor cells before any metastatic growth happens.

Key Points: 
  • Though circulating tumor cells technology is still under research phase but used for the prognosis of several cancer forms including, breast, melanoma, lung, colon, pancreas, and glioblastoma.\nIn the future, doctors would have a better chance of fighting cancer via liquid biopsies, and researchers would detect circulating tumor cells before any metastatic growth happens.
  • Currently, circulating tumor cell-based screening and analysis are at a nascent market stage.
  • The market dominance of cell-free DNA units over circulating tumor cells in cancer diagnosis has led to less share in clinical applications.
  • This high market growth is due to the fact that most of the products currently being on the market are primarily designed for research settings.